Hormone health (testosterone and menopause)
Menopause and perimenopause specialty launched in October 2025 under the Hers brand. Low-testosterone care was also launched in 2025.
What it is
Prescription treatment plans for low testosterone in men and for menopause and perimenopause in women. Care is directed by a licensed provider who adjusts the plan over time. Menopause options named by the company include estradiol and progesterone in pill, patch or cream form.
Why it matters to the stock. Hormone health extends the subscription model into longer-term treatment, which the company says can deepen customer relationships. Its revenue contribution is not broken out.
News
No stories tagged to this project yet.